bioRxiv Science⌕ Search

Biology subjects

Nguyen, V. C. B.

Publications and source records attributed to Nguyen, V. C. B..

2 recordsLinked to original sources

A domain-swapped CaMKII conformation facilitates linker-mediated allosteric regulation

Memory formation, fertilization, and cardiac function rely on precise Ca2+ signaling and subsequent Ca2+/calmodulin-dependent protein kinase II (CaMKII) activation. Ca2+ sensitivity of the four CaMKII paralogs in mammals has been linked to the length of the variable linker region that is a hot spot for alternative splicing. In this study, we determined that the position of charged residues within the linker modulates the Ca2+/CaM sensitivity. We present an X-ray crystal structure of the full-length CaMKII{delta} holoenzyme consisting of domain-swapped dimers within a dodecameric complex. In this structure, the kinase domain of one subunit is docked onto the hub domain of an adjacent subunit, providing an additional interface within the holoenzyme. Mutations at the hub equatorial and lateral interfaces led to alterations in the stoichiometry of CaMKII holoenzyme as well as Ca2+/CaM sensitivity. Using molecular dynamics (MD) to compare domain-swapped to non-domain-swapped CaMKIIs, we demonstrate that the domain-swapped conformation facilitates an interaction between the calmodulin binding region and the linker region. Based on MD simulations and small-angle X-ray scattering (SAXS) measurements, we propose a model where the position of charges on the linker region drives an interaction with the regulatory segment that modulates the degree of autoinhibition. Finally, we use live-cell imaging to show that the activation profiles we observe in vitro are recapitulated in cells. Our findings provide a new framework for understanding allosteric regulation of CaMKII by the linker region in Ca2+-sensitive cells.

biochemistry↗

Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancer

The PEAK family of pseudokinases, comprising PEAK1-3, are signalling scaffolds that play oncogenic roles in several poor prognosis human cancers, including triple negative breast cancer (TNBC). However, therapeutic targeting of pseudokinases is challenging due to their lack of catalytic activity. To address this, we screened for PEAK1 effectors by affinity purification and mass spectrometry, identifying calcium/calmodulin-dependent protein kinase 2 (CAMK2)D and CAMK2G. PEAK1 promoted CAMK2D/G activation in TNBC cells via a novel feed-forward mechanism involving PEAK1/PLC{gamma}1/Ca2+ signalling and direct binding via a consensus CAMK2 interaction motif in the PEAK1 N-terminus. In turn, CAMK2 phosphorylated PEAK1 to enhance association with PEAK2, which is critical for PEAK1 oncogenic signalling. To achieve pharmacologic targeting of PEAK1/CAMK2, we repurposed RA306, a second generation CAMK2 inhibitor under pre-clinical development for treatment of cardiovascular disease. RA306 demonstrated on-target activity against CAMK2 in TNBC cells and inhibited PEAK1-enhanced migration and invasion in vitro. Moreover, RA306 significantly attenuated TNBC xenograft growth and blocked metastasis in a manner mirrored by CRISPR-mediated PEAK1 ablation. Overall, these studies establish PEAK1 as a critical cell signalling nexus, identify a novel mechanism for regulation of Ca2+ signalling and its integration with tyrosine kinase signals, and identify CAMK2 as a therapeutically actionable target downstream of PEAK1.

cancer biology↗